Medication info
SOPM Tablet 40 mg (Esomeprazole Magnesium Trihydrate)

SOPM Tablet 40 mg (Esomeprazole Magnesium Trihydrate)

Prescription medicationTabletOral · Intravenous injection
Ingredient · strength
Esomeprazole Magnesium Trihydrate›44.5mg / 1 tablet
Manufacturer / importer
Mothers Pharmaceutical Co., Ltd.
Appearance
Pink round film-coated tablet
Packaging
28 tablets (14 tablets/Alu-Alu×2), 28 tablets (7 tablets/Alu-Alu×4)
Approval status
Active

MFDS item code 201603062 · Approved 2016.05.30 · Insurance code 622802660

Summary

Main use
Treatment of gastroesophageal reflux, gastrointestinal disorders (including eradication therapy, ulcers, and drug-related symptoms), and Zollinger-Ellison syndrome
Who uses it
Adults · Children
Adult dosage
This medicine should be swallowed with a liquid such as water and should not be chewed or crushed. Treatment of erosive reflux esophagitis: 40 mg once daily for 4 weeks. Patients whose esophagitis has not healed or whose symptoms persist should continue treatment for an additional 4 weeks. Long-term maintenance therapy to prevent recurrence in patients with esophagitis: 20 mg once daily Symptomatic treatment of gastroesophageal reflux disease without esophagitis: 20 mg once daily. If symptoms are not controlled after 4 weeks, further evaluation is needed. Symptomatic treatment of gastroesophageal reflux disease without esophagitis: Once symptoms have resolved, subsequent recurrent symptoms may be controlled by taking 20 mg once daily. In adults, 20 mg may be taken once daily as needed. On-demand treatment to control recurrent symptoms is not recommended for patients at high risk of developing gastric or duodenal ulcers due to nonsteroidal anti-inflammatory drug use. Combination therapy with antibiotics for Helicobacter pylori eradication: Administer this medicine 20 mg with amoxicillin 1 g and clarithromycin 500 mg twice daily for 7 days. Short-term treatment of upper gastrointestinal symptoms (pain, discomfort, burning sensation) associated with nonsteroidal anti-inflammatory drug use (nonselective or selective COX-2 inhibitors): 20 mg once daily. If symptoms are not controlled after 4 weeks, further evaluation is needed. Clinical trials lasting longer than 4 weeks have not been conducted. Treatment of gastric ulcers associated with nonsteroidal anti-inflammatory drug use: 20 mg once daily. The treatment duration is 4∼8 weeks. Prevention of gastric and duodenal ulcers associated with nonsteroidal anti-inflammatory drug use: 20 mg once daily. Treatment of Zollinger-Ellison syndrome: The recommended initial dose is 40 mg twice daily. The dose should then be adjusted for each patient, and treatment should continue while clinical symptoms are present. Clinical data indicate that most patients can be controlled with doses of 80 ∼ 160 mg per day. Doses above 80 mg per day should be divided and taken twice daily. Maintenance therapy after intravenous induction to prevent rebleeding from gastric or duodenal ulcers: Administer 40 mg once daily for 4 weeks after intravenous induction to prevent rebleeding from gastric or duodenal ulcers. Renal impairment: No dose adjustment is necessary. Use with caution because there is limited experience administering this medicine to patients with severe renal impairment. Hepatic impairment: No dose adjustment is necessary in patients with mild to moderate hepatic impairment. In patients with severe hepatic impairment, the dose of this medicine should not exceed 20 mg. Older adults: No dose adjustment is necessary.
Children's dosage
Adolescents aged 12 years and older — Treatment of erosive reflux esophagitis: 40 mg once daily for 4 weeks. Patients whose esophagitis has not healed or whose symptoms persist should continue treatment for an additional 4 weeks. Adolescents aged 12 years and older — Symptomatic treatment of gastroesophageal reflux disease without esophagitis: 20 mg once daily. If symptoms are not controlled after 4 weeks, further evaluation is needed. Adolescents aged 12 years and older — Symptomatic treatment of gastroesophageal reflux disease without esophagitis: Once symptoms have resolved, subsequent recurrent symptoms may be controlled by taking 20 mg once daily. Children under 12 years: There is no experience with administration of this medicine to children under 12 years of age.

Ingredients

Manufacturer
Mothers Pharmaceutical Co., Ltd.

Efficacy & effects

Treatment of gastroesophageal reflux, gastrointestinal disorders (including eradication therapy, ulcers, and drug-related symptoms), and Zollinger-Ellison syndrome

  • Gastroesophageal reflux disease
  • erosive reflux esophagitis
  • esophagitis
  • duodenal ulcers
  • peptic ulcers
  • upper gastrointestinal pain
  • upper gastrointestinal discomfort
  • upper gastrointestinal burning sensation
  • gastric ulcers
  • duodenal ulcers
  • Zollinger-Ellison syndrome
  • gastric ulcer rebleeding
View approved original text

This medication is used for the treatment of gastroesophageal reflux disease, especially for erosive reflux esophagitis and for long-term maintenance therapy to prevent recurrence in patients with esophagitis. It also helps alleviate symptoms of gastroesophageal reflux disease without esophagitis. It is effective for the treatment and prevention of recurrence of patients with duodenal ulcers or peptic ulcers accompanied by Helicobacter pylori infection. It is used for the short-term treatment of upper gastrointestinal symptoms associated with the use of non-steroidal anti-inflammatory drugs and also for the treatment and prevention of gastric ulcers in patients who require long-term use. Additionally, it is utilized for the treatment of Zollinger-Ellison syndrome and the preventive maintenance therapy for rebleeding caused by gastric or duodenal ulcers. Overall, this medication aids in the treatment of gastrointestinal diseases and improvement of symptoms.

Dosage and Administration

Adult dosage

This medicine should be swallowed with a liquid such as water and should not be chewed or crushed. Treatment of erosive reflux esophagitis: 40 mg once daily for 4 weeks. Patients whose esophagitis has not healed or whose symptoms persist should continue treatment for an additional 4 weeks. Long-term maintenance therapy to prevent recurrence in patients with esophagitis: 20 mg once daily Symptomatic treatment of gastroesophageal reflux disease without esophagitis: 20 mg once daily. If symptoms are not controlled after 4 weeks, further evaluation is needed. Symptomatic treatment of gastroesophageal reflux disease without esophagitis: Once symptoms have resolved, subsequent recurrent symptoms may be controlled by taking 20 mg once daily. In adults, 20 mg may be taken once daily as needed. On-demand treatment to control recurrent symptoms is not recommended for patients at high risk of developing gastric or duodenal ulcers due to nonsteroidal anti-inflammatory drug use. Combination therapy with antibiotics for Helicobacter pylori eradication: Administer this medicine 20 mg with amoxicillin 1 g and clarithromycin 500 mg twice daily for 7 days. Short-term treatment of upper gastrointestinal symptoms (pain, discomfort, burning sensation) associated with nonsteroidal anti-inflammatory drug use (nonselective or selective COX-2 inhibitors): 20 mg once daily. If symptoms are not controlled after 4 weeks, further evaluation is needed. Clinical trials lasting longer than 4 weeks have not been conducted. Treatment of gastric ulcers associated with nonsteroidal anti-inflammatory drug use: 20 mg once daily. The treatment duration is 4∼8 weeks. Prevention of gastric and duodenal ulcers associated with nonsteroidal anti-inflammatory drug use: 20 mg once daily. Treatment of Zollinger-Ellison syndrome: The recommended initial dose is 40 mg twice daily. The dose should then be adjusted for each patient, and treatment should continue while clinical symptoms are present. Clinical data indicate that most patients can be controlled with doses of 80 ∼ 160 mg per day. Doses above 80 mg per day should be divided and taken twice daily. Maintenance therapy after intravenous induction to prevent rebleeding from gastric or duodenal ulcers: Administer 40 mg once daily for 4 weeks after intravenous induction to prevent rebleeding from gastric or duodenal ulcers. Renal impairment: No dose adjustment is necessary. Use with caution because there is limited experience administering this medicine to patients with severe renal impairment. Hepatic impairment: No dose adjustment is necessary in patients with mild to moderate hepatic impairment. In patients with severe hepatic impairment, the dose of this medicine should not exceed 20 mg. Older adults: No dose adjustment is necessary.

Children's dosage

Adolescents aged 12 years and older — Treatment of erosive reflux esophagitis: 40 mg once daily for 4 weeks. Patients whose esophagitis has not healed or whose symptoms persist should continue treatment for an additional 4 weeks. Adolescents aged 12 years and older — Symptomatic treatment of gastroesophageal reflux disease without esophagitis: 20 mg once daily. If symptoms are not controlled after 4 weeks, further evaluation is needed. Adolescents aged 12 years and older — Symptomatic treatment of gastroesophageal reflux disease without esophagitis: Once symptoms have resolved, subsequent recurrent symptoms may be controlled by taking 20 mg once daily. Children under 12 years: There is no experience with administration of this medicine to children under 12 years of age.

Precautions

This medication should not be used in patients who have had an allergic reaction to this drug or its constituents, or to benzimidazole. Additionally, patients with hypersensitivity to penicillin antibiotics or macrolide antibiotics should be careful when using this drug concomitantly. Serious interactions may occur when this medication is used together with specific heart-related drugs or antiviral agents, hence patients taking such medications should not use this medicine. It is not recommended for women who are breastfeeding, and patients with a history of myocardial infarction should also avoid it. During treatment with this medication, various side effects may occur, such as blood abnormalities, allergic reactions, gastrointestinal disturbances, and liver function abnormalities, so if any symptoms appear, immediate consultation with a physician is necessary. It is important to conduct regular checks for adverse reactions if taken for a long time. This medication can inhibit gastric acid secretion, which may promote bacterial overgrowth in the gastrointestinal tract, so if diarrhea or signs of infection persist, consultation with healthcare providers is needed. Also, long-term use may increase the risk of fractures, thus caution is needed in patients with osteoporosis. Interactions may occur when taken with other medications, so it's important to inform healthcare providers of all medications being taken. During pregnancy, the safety of this drug has not been fully established, so it should be used with caution in pregnant women, and breastfeeding women are advised not to take it. In case of overdose, there is no specific antidote, so treatment must be based on the symptoms, and it should be kept out of reach of children.

Side effects

Leukopenia, thrombocytopenia, agranulocytosis, pancytopenia, fever, angioedema, anaphylactic reaction, shock, peripheral edema, hyponatremia, hypomagnesemia, insomnia, anxiety, mental confusion, depression, aggression, hallucination, headache, dizziness, paresthesia, drowsiness, taste disorder, blurred vision, bronchospasm, pancreatitis, abdominal pain, constipation, diarrhea, abdominal distension, nausea, vomiting, xerostomia, stomatitis, gastrointestinal candidiasis, microscopic colitis, elevated liver enzymes, jaundice, hepatitis, liver failure, encephalopathy, dermatitis, itching, rash, urticaria, hair loss, photosensitivity, erythema multiforme, Stevens-Johnson syndrome, toxic epidermal necrolysis, acute generalized exanthematous pustulosis, drug reactions associated with eosinophilia and systemic symptoms, fractures, arthralgia, myalgia, muscle weakness, nephritis, gynecomastia, asthenia, increased sweating, Clostridium difficile-associated diarrhea, abdominal distension, allergic reaction, back pain, chest pain, sternal chest pain, facial edema, facial flushing, fatigue, fever, influenza-like illness, generalized edema, leg edema, lethargy, pain, rigidity, peripheral edema, flushing, hypertension, tachycardia, thyroid swelling, irritable bowel syndrome, worsening of constipation, dyspepsia, dysphagia, gastrointestinal motility disorder, epigastric pain, belching, esophageal disorder, frequent bowel movements, gastroenteritis, gastrointestinal bleeding, hiccups, melena, oral disorder, pharyngeal disorder, rectal disorder, gastrointestinal symptoms, elevated serum gastrin levels, tongue disorder, tongue swelling, ulcerative stomatitis, vomiting, earache, tinnitus, anemia, hypopigmented anemia, cervical lymphadenopathy, nosebleed, leukocytosis, leukopenia, thrombocytopenia, hyperbilirubinemia, liver dysfunction, increased ALT, increased AST, diabetes, hyperuricemia, increased ALP, thirst, vitamin B12 deficiency, weight gain, weight loss, worsening of arthritis, arthropathy, convulsions, fibromyalgia syndrome, hernia, rheumatoid polymyalgia, arthralgia, loss of appetite, apathy, increased appetite, confusion, worsening of depression, hypertonic muscle syndrome, anxiety, sensory loss, erectile dysfunction, insomnia, migraine, worsening of migraine, sleep disorder, tremors, dizziness, visual field defect, paresthesia, drowsiness, dysmenorrhea, menstrual disorder, vaginitis, worsening of asthma, cough, dyspnea, laryngeal edema, pharyngitis, rhinitis, sinusitis, acne, anal itching, rash, erythematous rash, papular rash, angioedema, dermatitis, itching, urticaria, increased sweating, otitis media, altered sense of smell, taste loss, taste disturbance, urinary abnormalities, albuminuria, cystitis, dysuria, fungal infection, hematuria, urinary frequency, candidiasis, genital candidiasis, polyuria, conjunctivitis, visual disturbances, duodenitis, esophagitis, esophageal stricture, esophageal ulcer, esophageal varices, gastric ulcer, gastritis, benign polyps or nodules, Barrett's esophagus, mucosal discoloration, hernia, systemic lupus erythematosus, cutaneous lupus erythematosus, hypocalcemia, hypokalemia, rhabdomyolysis

Not everyone experiences these, and they can vary from person to person.

Storage

This medication should be stored in a tightly closed container to avoid exposure to air or moisture, and it is recommended to be kept at room temperature between 1 and 30 degrees Celsius. Storing it this way helps maintain the efficacy of the medication and ensures safe usage.

Appearance and packaging

Appearance

Pink round film-coated tablet

Package unit

28 tablets (14 tablets/Alu-Alu×2), 28 tablets (7 tablets/Alu-Alu×4)

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.